Table 1.
Female, % | Age, yrs, median (IQR) |
RF ELISA Positive, % |
Anti-CCP ELISA Positive, % |
RF ELISA Positive and Anti-CCP ELISA Positive, % |
|
---|---|---|---|---|---|
WG, n = 10 | 70 | 62 (44.5–77) | 0 | 0 | 0 |
SLE, n = 10 | 90 | 59 (34.5–74) | 40 | 10 | 10 |
AS, n = 12 | 17 | 47 (37–50.5) | 0 | 0 | 0 |
Inflammatory bowel disease, n = 10 |
50 | 62.5 (52–74.5) | 30 | 20 | 10 |
Sarcoidosis, n = 10 | 30 | 48.5 (37.5–64) | 10 | 0 | 0 |
OA, n = 10 | 60 | 60.5 (49–72) | 10 | 0 | 0 |
Hyperlipidemia, n = 20 | 40 | 56 (47–60) | 0 | 0 | 0 |
Seropositive RA, n = 22 | 57 | 70 (62.5–74) | 100 | 86 | 86 |
Seronegative RA*, n = 20 | 70 | 62 (53.5–72) | 15 | 25 | 10 |
Seronegative RA defined on the basis of RF tested by latex agglutination. WG: Wegener’s granulomatosis, SLE: systemic lupus erythematosus, AS: ankylosing spondylitis, OA: osteoarthritis; RA: rheumatoid arthritis.